Cyramza 2016 U.S. PROMOTIONAL AUDIT REPORT

Published July 2017 • 24 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Cyramza through personal promotion in 2016 and how does this compare to its peer set in the Colorectal Cancer, Gastric Cancer, and Non-Small Cell Lung Cancer markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Eli Lilly’s depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, Internal Medicine, and Radiation Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Cyramza throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers for Cyramza in 2016?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
• Over 11,000 paid interactions across 4,000 physicians made on behalf of Cyramza were carefully examined to support our analysis. In addition, interaction data from 19 peer products (e.g. Abraxane, Alecensa, Alimta, Avastin, Erbitux, Gilotrif, Herceptin, Iressa, Keytruda, Lonsurf, Opdivo, Portrazza, Stivarga, Tagrisso, Tarceva, Tecentriq, Vectibix, Xalkori, and Zykadia ) was leveraged to provide benchmarking and market insights.